Alimta

... Nice Quarter for Lilly Pfizer's Cholesterol ProblemSigma-Aldrich in Oxford Biomedica LinkAndrx Hopes to Pass FDA Review Quotes Site Search Advanced Search Let our experts point you to low-priced picks that could potentially pay off big.

Check out today's ideas...

William GabrielskiDavid Peltier Sponsored by TheStreet.com Stocks Under $10 Learn More Jim Cramer's top stock picksStocks Under $10 - View our favorite stock picks!

Stock News : Biotech/Pharmaceuticals A.sponsor:link, A.sponsor:visited {color:#CC3300;text-decoration: none} A.sponsor:hover {color:#CC3300;text-decoration: underline} Sponsored by TheStreet.com Internet Review Nice Quarter for Lilly By TSC Staff 10/20/2005 7:42 AM EDT Third-quarter earnings rose 5% from a year ago to $794.4 million, or 73 cents a share, at Eli Lilly (LLY:NYSE - commentary - research - Cramer's Take), as a handful of newer drugs drove sales growth.

In the comparable quarter last year, Lilly earned $755.2 million, or 69 cents a share.

Sales rose 10% from a year ago to $3.60 billion.

On average, analysts had been forecasting earnings of 71 cents a share in the latest quarter on sales of $3.62 billion.

For the fourth quarter, Lilly put earnings at 73 cents to 79 cents a share, compared with the Thomson First Call consensus estimate of 76 cents a share.

Among its big sellers, Lilly said third-quarter revenue for schizophrenia treatment Zyprexa rose 1% from a year ago to $1.04 billion, while sales in its diabetes category rose 13% to $652...

... Bloomberg.com: U.S.

Updated: New York: Oct 20 09:00London: Oct 20 14:00Tokyo: Oct 20 22:00 US AUBZFPGRHKIMJPLNSMIND : Regions Top Worldwide Regions Asia Australia & New Zealand Canada Europe Germany Japan Latin America U.K.

U.S.

Markets Economy/Politics Commentary Sports Culture RESOURCES: Bloomberg TV Bloomberg Radio Markets U.S.

E-Mail This Story Printer-Friendly Format Pfizer's Earnings Plunge 52 Percent on Lower Sales of Celebrex Painkiller Ford Posts Loss of $284 Million on Lower SUV Sales, Its First Since 2003 Eli Lilly Net Income Rises on Sales of Antidepressants, Cancer Treatments Lilly's 3rd-Qtr Profit Rises 5.2% on New Drugs (Update1) Oct.

20 (Bloomberg) - Eli Lilly & Co.

said third-quarter profit rose 5.2 percent as increased sales of its Cymbalta antidepressant and Alimtra cancer drug helped counter sluggish growth of its best-seller Zyprexa schizophrenia drug.

Net income for Lilly rose to $794.4 million, or 73 cents a share, from $755 million, or 69 cents, a year earlier, Indianapolis-based Lilly said in a statement issued on PR news wire.

Sales rose 10 percent to $3.6 billion.

Lilly is planning on saving $150 million this year through costs cuts, including job reductions announced in 2004, according to the company Web site.

U.S.

sales of Zyprexa and the Strattera attention-deficit-disorder drug fell on concerns about side affects, analysts say.

Zyprexa is the world's top-selling schizophrenia drug and Lilly's b...

... PharmaLive: Lilly Reports $.73 EPS and 10 Percent Sales Growth in the Third Quarter REGISTERED USERS TODAY ON PHARMALIVE.COM Lilly Reports $.73 EPS and 10 Percent Sales Growth in the Third Quarter Newer Products Contribute More Than $650 Million, or 18 Percent of Total Q3 Sales INDIANAPOLIS, October 20, 2005 /PRNewswire-FirstCall/ - Eli Lilly and Company today announced financial results for the third quarter of 2005.

Third-Quarter Highlights * Sales increased 10 percent, to $3.601 billion.

* Newer products - * Cymbalta, which was launched in the U.S.

in late August 2004 for the treatment of major depressive disorder and in September 2004 for the treatment of diabetic peripheral neuropathic pain, has achieved $544.8 million in U.S.

sales since its launch.

* As detailed in the Lilly ICOS third-quarter earnings results, the Lilly ICOS joint venture generated positive earnings this quarter of $19.8 million.

* Net income and earnings per share increased 5 percent and 6 percent, to $794.4 million and $.73, respectively, compared with reported third-quarter 2004 net income of $755.2 million and $.69 per share.

* Assuming stock option expensing in 2004, the third-quarter 2005 net income an...